Re­gen­eron an­ti­body se­cures FDA win; Yan­copou­los in ex­pan­sive Q&A; Bio­gen’s Rea­ta bid­ding war de­tails re­vealed; Pe­ter Marks on ac­cel­er­at­ed ap­provals; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

With most sec­ond quar­ter earn­ings in the rearview mir­ror, we’ve been lock­ing in in­ter­views with key fig­ures in biotech and phar­ma. While we have more Q&As in the pipeline, we’ll ask you this ques­tion: Who would you like us to chat with? Email us to have your say. — Rey­nald Cas­tañe­da

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER